Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
vandetanib epidermal growth factor receptor small molecule Successful target TTD , drugbank , DGIDB Heart failure[MeSHID:D006333]
Long QT Syndrome[MeSHID:D008133]
Disease[MeSHID:D004194]
Heart[MeSHID:D006321]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.17 approved inhibitor
vandetanib vascular endothelial growth factor receptor 2 NA Successful target TTD , DGIDB Heart failure[MeSHID:D006333]
Long QT Syndrome[MeSHID:D008133]
Disease[MeSHID:D004194]
Heart[MeSHID:D006321]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.11 approved inhibitor
vandetanib vascular endothelial growth factor receptor 2 NA Successful target TTD , DGIDB Heart failure[MeSHID:D006333]
Long QT Syndrome[MeSHID:D008133]
Disease[MeSHID:D004194]
Heart[MeSHID:D006321]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.11 approved unknown
vandetanib protein-tyrosine kinase 6 small molecule NA drugbank , DGIDB Heart failure[MeSHID:D006333]
Long QT Syndrome[MeSHID:D008133]
Disease[MeSHID:D004194]
Heart[MeSHID:D006321]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.15 approved inhibitor
vandetanib proto-oncogene tyrosine-protein kinase receptor ret small molecule NA drugbank , DGIDB Heart failure[MeSHID:D006333]
Long QT Syndrome[MeSHID:D008133]
Disease[MeSHID:D004194]
Heart[MeSHID:D006321]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.81 approved unknown
vandetanib proto-oncogene tyrosine-protein kinase receptor ret small molecule NA drugbank , DGIDB Heart failure[MeSHID:D006333]
Long QT Syndrome[MeSHID:D008133]
Disease[MeSHID:D004194]
Heart[MeSHID:D006321]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.81 approved inhibitor
vandetanib proto-oncogene c-ret NA Successful target TTD , DGIDB Heart failure[MeSHID:D006333]
Long QT Syndrome[MeSHID:D008133]
Disease[MeSHID:D004194]
Heart[MeSHID:D006321]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.81 approved inhibitor
vandetanib proto-oncogene c-ret NA Successful target TTD , DGIDB Heart failure[MeSHID:D006333]
Long QT Syndrome[MeSHID:D008133]
Disease[MeSHID:D004194]
Heart[MeSHID:D006321]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.81 approved unknown
vandetanib angiopoietin-1 receptor small molecule NA drugbank , DGIDB Heart failure[MeSHID:D006333]
Long QT Syndrome[MeSHID:D008133]
Disease[MeSHID:D004194]
Heart[MeSHID:D006321]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.07 approved inhibitor
vandetanib vascular endothelial growth factor a small molecule NA drugbank Heart failure[MeSHID:D006333]
Long QT Syndrome[MeSHID:D008133]
Disease[MeSHID:D004194]
Heart[MeSHID:D006321]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 NA approved inhibitor
click here to return to the previous page